These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Chigrinova E; Rinaldi A; Kwee I; Rossi D; Rancoita PM; Strefford JC; Oscier D; Stamatopoulos K; Papadaki T; Berger F; Young KH; Murray F; Rosenquist R; Greiner TC; Chan WC; Orlandi EM; Lucioni M; Marasca R; Inghirami G; Ladetto M; Forconi F; Cogliatti S; Votavova H; Swerdlow SH; Stilgenbauer S; Piris MA; Matolcsy A; Spagnolo D; Nikitin E; Zamò A; Gattei V; Bhagat G; Ott G; Zucca E; Gaidano G; Bertoni F Blood; 2013 Oct; 122(15):2673-82. PubMed ID: 24004666 [TBL] [Abstract][Full Text] [Related]
46. Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents. Tadmor T; Levy I Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680290 [TBL] [Abstract][Full Text] [Related]
48. Revisiting Richter transformation in the era of novel CLL agents. Petrackova A; Turcsanyi P; Papajik T; Kriegova E Blood Rev; 2021 Sep; 49():100824. PubMed ID: 33775465 [TBL] [Abstract][Full Text] [Related]
49. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. Eyre TA; Schuh A; Wierda WG; Brown JR; Ghia P; Pagel JM; Furman RR; Cheung J; Hamdy A; Izumi R; Patel P; Wang MH; Xu Y; Byrd JC; Hillmen P Lancet Haematol; 2021 Dec; 8(12):e912-e921. PubMed ID: 34735860 [TBL] [Abstract][Full Text] [Related]
50. Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. Gould C; Lickiss J; Kankanige Y; Yerneni S; Lade S; Gandhi MK; Chin C; Yannakou CK; Villa D; Slack GW; Markham JF; Tam CS; Nelson N; Seymour JF; Dickinson M; Neeson PJ; Westerman D; Blombery P Br J Haematol; 2021 Oct; 195(1):113-118. PubMed ID: 34426978 [TBL] [Abstract][Full Text] [Related]
51. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. Bulian P; Rossi D; Forconi F; Del Poeta G; Bertoni F; Zucca E; Montillo M; Pozzato G; D'Arena G; Efremov DG; Marasca R; Lauria F; Gaidano G; Gattei V; Laurenti L J Transl Med; 2012 Jan; 10():18. PubMed ID: 22289136 [TBL] [Abstract][Full Text] [Related]
52. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984 [TBL] [Abstract][Full Text] [Related]
53. SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation. Burke JM Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):427-435. PubMed ID: 35577753 [TBL] [Abstract][Full Text] [Related]
54. Richter transformation of chronic lymphocytic leukemia in the era of novel agents. Wang Y; Ding W Clin Adv Hematol Oncol; 2020 Jun; 18(6):348-357. PubMed ID: 32649656 [TBL] [Abstract][Full Text] [Related]
55. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. Wang Y; Sinha S; Wellik LE; Secreto CR; Rech KL; Call TG; Parikh SA; Kenderian SS; Muchtar E; Hayman SR; Koehler AB; Van Dyke DL; Leis JF; Slager SL; Dong H; Kay NE; He R; Ding W Blood Cancer J; 2021 May; 11(5):86. PubMed ID: 33972504 [TBL] [Abstract][Full Text] [Related]
59. Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway. Lenartova A; Randen U; Johannesen TB; Tjønnfjord GE Cancer Epidemiol; 2019 Jun; 60():128-133. PubMed ID: 30986631 [TBL] [Abstract][Full Text] [Related]